Ping An Biomedical Co., Ltd. key statistics and ratios

In fiscal 2025, Ping An Biomedical Co., Ltd. had return on equity of -66.7%, an operating margin of -43.1%, debt equal to 22.1% of equity and a current ratio of 2.76. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ping An Biomedical Co., Ltd.: financial ratios, annual
Fiscal year	2023Sept 2023	2024Sept 2024	2025Sept 2025
Gross margin	5.1%	6.2%	2.8%
Operating margin	0.7%	−0.0%	−43.1%
Net margin	−1.2%	−1.5%	−37.6%
Return on equity	—	—	−66.7%
Return on assets	—	−2.2%	−20.1%
Asset turnover	—	1.50	0.53
Current ratio	—	0.84	2.76
Debt to equity	—	—	22.1%
Interest cover (operating income ÷ interest)	0.4x	n/m	n/m

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · September 30, 2025

What it owns · $10m

Short-term assets $9mLonger-term assets $1m

What it owes, and who funded it · $10m

Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $6m

Short-term assets cover short-term liabilities $9m of assets due within a year against $3m of liabilities due within a year.
Short-term assets cover long-term liabilities $9m short-term assets against $13,443 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$2m against $42,577 of interest.

From Ping An Biomedical Co., Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: NTRP vs PASW PASW vs XELB PASW vs UZX

More: Consumer Discretionary sector, rankings of US companies

Figures from Ping An Biomedical Co., Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Ping An Biomedical Co., Ltd.